Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.

摘要: Purpose Options for single-agent fluoropyrimidine adjuvant therapy after bowel cancer resection include intravenous fluorouracil with leucovorin (FU/LV) or oral capecitabine. These treatments have similar efficacy but differ in convenience and toxicity. We therefore wished to compare their overall acceptability patients. Patients Methods scheduled were randomly assigned receive once-weekly FU/LV (425 mg/m2 FU, 45 mg LV) 6 weeks, followed by two 3-week cycles of capecitabine (1,250 twice daily, days 1 through 14), the same reverse order. After 12 patients asked which treatment they preferred, received preferred an additional weeks. The primary end point was patient preference. Results 40 planned 74 had been assigned, real-time adverse event monitoring led early trial closure because excess sequence-specific Eleven 14 ...